Scholar Rock Holding Corporation
SRRKDrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
3
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
3 upcoming, 0 past
SRRK Earnings Report
EPS Est: $-0.84 | FQ end 2026-06 | Call: 2026-08-06 15:00:00
2 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How SRRK's past catalysts played out
Apitegromab
Spinal Muscular Atrophy
Tirzepatide
Overweight and Obesity
SRK-015
Spinal Muscular Atrophy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Apitegromab | Phase 3 | Spinal Muscular Atrophy | - | - |
Tirzepatide | Phase 2 | Overweight and Obesity | - | - |
SRK-015 | Phase 2 | Spinal Muscular Atrophy | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Scholar Rock Holding Corporation's drug pipeline?→
CatalystAlert tracks 3 drug candidates in Scholar Rock Holding Corporation's (SRRK) pipeline across Phase 3, Phase 2. Its lead program is Apitegromab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Scholar Rock Holding Corporation's next FDA catalyst?→
Scholar Rock Holding Corporation's (SRRK) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SRRK biotech catalysts?→
Add SRRK to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Scholar Rock Holding Corporation's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.